A randomized placebo-controlled clinical study of nab-paclitaxel as second-line chemotherapy for patients with advanced non-small cell lung cancer in China

We performed a randomized and placebo-controlled clinical study to investigate whether nab-paclitaxel can improve survival in patients with advanced non-small cell lung cancer (NSCLC) after unsuccessful first-line chemotherapy. Patients with stages III to IV advanced NSCLC after first-line platinum-...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yueming, Feng, Jiang, Hu, Weiwei, Luo, Qingquan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2017
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5529204/
https://www.ncbi.nlm.nih.gov/pubmed/28356484
http://dx.doi.org/10.1042/BSR20170020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5529204/
https://www.ncbi.nlm.nih.gov/pubmed/28356484
http://dx.doi.org/10.1042/BSR20170020

Ejemplares similares